The 23rd annual PepTalk, held from January 16-19, 2024, marked a significant gathering in the biotech and pharmaceutical field. The conference showcased the latest advancements in protein science and production, with illuminating keynote sessions. The key topics in discussion were:
Antibody discovery and engineering
AI-driven tools and interpretable machine learning models were the focus for identifying, designing, and optimizing high-affinity antibodies.
Many improvements were made in integrating machine learning into discovery and engineering platforms, as well as high-throughput assays.
Bispecific antibody development
To improve the chance of success, speakers discussed novel formats for developability such as heterodimeric IgA Fc, CD3ε-targeting antibodies, and Fc-free antibody formats.
Bispecific antibody-drug conjugates (bsADCs) were of particular interest, as they have revolutionized cancer treatment. Their safety and efficacy were discussed, and Astrazeneca presented AZD9592, a first-in-class bsADC.
Characterization and aggregation in biopharmaceuticals
Developability and characterization for novel biologics were discussed, involving new applications in advanced mass spectrometry and multi-attribute method (MAM).
The mechanism and impact of protein aggregation were discussed, e.g. long-term storage of biologics in the frozen state, and the strategies for managing it.
Vector design and delivery
Issues with immunogenicity, limited cargo capacity, targeted delivery, purification, and complex regulatory considerations were discussed.
Viral and non-viral vector engineering and scale-up considerations such as with bioreactors and engineered hosts were displayed.
Higher-throughput (HTP) bioproduction
Decreasing delivery times for the exponentially growing needs of research and manufacturing pipelines were an important topic.
HTP techniques in engineering hosts, developing cell lines, and optimizing cell culture for protein expression, purification and quantification speeds up bioproduction platforms.
Thank you to all who came to visit our booth at PepTalk! It was a pleasure to chat with you and feel free to contact us for any follow-up questions, at info@biointron.com.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
